Gene Patent Reform: Still in DoubtThe patent-eligibility doctrine remains in limbo as the battle over gene patents cuts a tortuous path through the court system.

JOANNA T. BROUGHER

首页> 外文期刊>Biotechnology healthcare >Gene Patent Reform: Still in DoubtThe patent-eligibility doctrine remains in limbo as the battle over gene patents cuts a tortuous path through the court system.

【24h】

Gene Patent Reform: Still in DoubtThe patent-eligibility doctrine remains in limbo as the battle over gene patents cuts a tortuous path through the court system.

机译：基因专利改革：仍存疑问随着对基因专利的争夺在法院系统中走过一条曲折的道路，专利资格原则仍然处于困境。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

A the biotechnology industry has evolved, patent law has expanded to provide protection for an increasing number of technologies. The Supreme Court, however, has been taking a more restrictive approach to patent protection. Now that the Myriad Genetics gene patent case may be headed to the high court, biotechs conducting genetic research and developing diagnostic tests along with other healthcare stakeholders are asking what will the outcome really mean and what effect will it have on personalized medicine.

机译：随着生物技术产业的发展，专利法也不断扩展，为越来越多的技术提供保护。但是，最高法院对专利保护采取了更为严格的方法。既然Myriad Genetics基因专利案件可能会提交高等法院审理，进行基因研究和开发诊断测试的生物技术公司将与其他医疗保健利益相关方一起询问，结果将真正意味着什么以及它将对个性化医疗产生什么影响。

著录项

来源
《Biotechnology healthcare》 |2011年第4期|共2页
作者
JOANNA T. BROUGHER;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词

相似文献

外文文献
专利

1. Gene Patent Reform: Still in DoubtThe patent-eligibility doctrine remains in limbo as the battle over gene patents cuts a tortuous path through the court system. [J] . JOANNA T. BROUGHER Biotechnology healthcare . 2011,第4期

机译：基因专利改革：仍存疑问随着对基因专利的争夺在法院系统中走过一条曲折的道路，专利资格原则仍然处于困境。
2. Bilski: Assessing the Impact of a Newly Invigorated Patent-Eligibility Doctrine on the Pharmaceutical Industry and the Future of Personalized Medicine [J] . Christopher M. Holman Current Topics in Medicinal Chemistry . 2010,第18期

机译：Bilski：评估全新的专利资格学说对制药行业和个性化医学未来的影响
3. Losing the Home-Team Advantage: The Supreme Court's Narrowing of the Doctrine of General Personal Jurisdiction and Its Impact on Patent Declaratory Judgment Actions [J] . Ankur Parekh, Mark D. Giarratana, Abraham S. Robinson Intellectual property & technology law journal . 2014,第9期

机译：失去家庭团队优势：最高法院对一般人身管辖权原则的缩小及其对专利宣告判决行为的影响
4. The Impact of the Recent U.S. Supreme Court Decisions and Proposed New U.S. Patent and Trademark Office Rules and Patent Reform Legislation on Patent Acquisition, Exploitation, Enforcement and Defense Strategies [C] . M.M. Zoltick, J.A. Hynds, D. V. Scaltrito Society of Vacuum Coaters Annual Technical Conference . 2008

机译：美国最高法院最近的裁决以及拟议的美国专利商标局新规则和专利改革立法对专利获取，利用，执行和防御策略的影响
5. An "Obvious" Proposal -- Using An Industry-Sensitive Doctrine of Obviousness to Govern the Scope of Gene Patents After Association For Molecular Pathology v. USPTO. [D] . Engle, Sarah Noelle. 2011

机译：一项“显而易见的”提案-在针对分子病理学协会诉USPTO案之后，使用一种行业敏感性的显而易见性原则来控制基因专利的范围。
6. The patent law Duchy of Grand Fenwick: a comment on The mouse that trolled: the long and tortuous history of a gene mutation patent that became an expensive impediment to Alzheimers research [O] . Joshua D. Sarnoff 2015

机译：芬威克大公国的专利法：对巨魔老鼠的评论：基因突变专利的悠久曲折历史成为阿尔茨海默氏症研究的昂贵障碍
7. Patent-Eligibility in the U. S. Cases- Focusing on ‘Prometheus’ Decision of the Supreme Court [O] . Jaeseop Song 2012

机译：在美国的专利资格。案件关注最高法院的“普罗米修斯”决定

Gene Patent Reform: Still in DoubtThe patent-eligibility doctrine remains in limbo as the battle over gene patents cuts a tortuous path through the court system.

摘要

著录项

相似文献

相关主题

期刊订阅